Get the Stockscreener App
1.37
4.20%
-0.06
Cardiol Therapeutics Inc stock is traded at $1.37, with a volume of 194.60K.
It is down -4.20% in the last 24 hours and up +23.42% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.43
Open:
$1.42
24h Volume:
194.60K
Relative Volume:
1.00
Market Cap:
$119.84M
Revenue:
-
Net Income/Loss:
$-21.65M
P/E Ratio:
-4.1253
EPS:
-0.3321
Net Cash Flow:
$-15.84M
1W Performance:
-5.52%
1M Performance:
+23.42%
6M Performance:
+0.00%
1Y Performance:
-37.73%
1-Day Range:
$1.36
$1.4393
1-Week Range:
$1.3536
$1.50
52-Week Range:
$0.7709
$2.63
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.37 | 119.84M | 0 | -21.65M | -15.84M | -0.3321 |
|
RGC
Regencell Bioscience Holdings Ltd
|
78.00 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
161.67 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.50 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.89 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.89 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
(CRDL) Investment Analysis (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics (TSE:CRDL) Trading Up 2.1% – Here’s What Happened - Defense World
(CRDL) Stock Market Analysis (CRDL:CA) - news.stocktradersdaily.com
Analysts Issue Forecasts for CRDL Q2 Earnings - Defense World
All Eyes On ARCHER: Will Cardiol's Drug For Heart Muscle Inflammation Hit The Mark? - RTTNews
(CRDL) Technical Pivots with Risk Controls (CRDL:CA) - news.stocktradersdaily.com
Cetera Investment Advisers Takes $56,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Now Covered by Analysts at HC Wainwright - Defense World
This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
HC Wainwright & Co. Initiates Coverage of Cardiol Therapeutics (CRDL) with Buy Recommendation - Nasdaq
Cardiol Therapeutics (CRDL): HC Wainwright & Co. Initiates Coverage with a Buy Rating and $9 Price Target | CRDL Stock News - GuruFocus
H.C. Wainwright Initiates Coverage on Cardiol Therapeutics (CRDL) With Positive Outlook | CRDL Stock News - GuruFocus
(CRDL) Strategic Investment Guide (CRDL:CA) - news.stocktradersdaily.com
RAD Reports Positive Preclinical Lu177-B7H3-mAb Data - Investing News Network
Former Eli Lilly CMO Joins Cardiol’s Board, Bolstering Drug Development, Clinical Trial, and Commercial Expertise - SECFilings.com
Cardiol Therapeutics Announces AGM Results and New Board Member - TipRanks
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | CRDL Stock News - GuruFocus
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders - Newsfile
Ex-Eli Lilly Chief Medical Officer Strengthens Cardiol Board as Critical Phase III Trial Nears Completion - Stock Titan
Cardiol Therapeutics Reports Q1 2025 Financial Results - TipRanks
Cardiol Therapeutics to Webcast Virtual Annual General Meeting o - GuruFocus
(CRDL) Market Insights and Trading Signals (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Inc. - Baystreet.ca
Stocks In Play: Cardiol Therapeutics Inc. - Barchart.com
Cardiol Therapeutics to Webcast AGM Amidst Ongoing Clinical Trials - TipRanks
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT - Newsfile
Cardiol Therapeutics Announces Virtual AGM: How Shareholders Can Participate Online May 28 - Stock Titan
Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Up 2.8% – Here’s Why - Defense World
(CRDL) Investment Performance Report (CRDL:CA) - news.stocktradersdaily.com
AMD Will Be as ‘Aggressive as Possible’ to Challenge Nvidia - The Globe and Mail
Cardiol Therapeutics (TSE:CRDL) Stock Price Down 5.2% – Time to Sell? - Defense World
(CRDL) Market Performance Analysis (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Strategic Equity Report (CRDL:CA) - news.stocktradersdaily.com
Acceleration of RAD204 Phase 1 dose escalation trial - Investing News Network
(CRDL) Advanced Trading Insights (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Given Consensus Rating of “Buy” by Analysts - Defense World
Envestnet Asset Management Inc. Makes New Investment in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Lodgement of CONNEQT Pulse Device with the TGA - Investing News Network
(CRDL) Trading Performance and Risk Management (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Daily Stock Insights (CRDL:CA) - news.stocktradersdaily.com
March Quarterly Activities Report - Investing News Network
March Quarterly Appendix 4C - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Trading Up 6.7% – What’s Next? - Defense World
Profound Medical Corp. - Baystreet.ca
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors | CRDL Stock News - GuruFocus
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Board Amid Phase III Trial Progress - TipRanks
The S&P 500 Is Doing Something That Hasn't Been Seen in Nearly 100 Years. Here Are the 10 Most Important Stocks to Keep an Eye On. - The Globe and Mail
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors - Newsfile
Cardiol Therapeutics nominates ex-Eli Lilly CMO to board By Investing.com - Investing.com Canada
Cardiol Therapeutics announces annual shareholder meeting By Investing.com - Investing.com India
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):